# 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.

> **NCT05299593** · PHASE4 · UNKNOWN · sponsor: **Fondazione G.B. Bietti, IRCCS** · enrollment: 43 (estimated)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** tafluprost/timolol

## Key facts

- **NCT ID:** NCT05299593
- **Lead sponsor:** Fondazione G.B. Bietti, IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-04
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299593, "24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05299593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*